儿童过敏性哮喘特异性免疫治疗中Foxp3和白细胞介素27mRNA的表达变化研究

The expression of Foxp3 and interleukin-27 in children with allergic asthma treated with specific immu- notherapy

目的探讨在过敏性哮喘尘螨特异性免疫治疗（SIT）过程中转录因子Foxp3、IL-27p28和EBI3mRNA在外周血单个核细胞中表达的变化。方法根据进行抗原特异性免疫治疗的时间，采集过敏性哮喘患儿39例，分离其SIT治疗前、治疗一年后和治疗两年后的外周静脉血单个核细胞，提取总RNA，逆转录成cDNA，利用荧光定量PCR的方法检测Foxp3、IL-27p28和EBI3mRNA的表达情况，并观察患儿治疗前后的临床疗效。结果随着SIT治疗的进行，患儿临床症状明显减轻，与SIT治疗前相比，治疗一年和两年后，外周血中Foxp3的mRNA表达水平明显升高，分别为治疗前的5．03倍和1．93倍，差异有统计学意义（P=0．0008，P=0．033）；IL-27EBI3的mRNA表达水平虽然有所升高，分别为治疗前的1．56倍和1．32倍，但差异并没有统计学意义（P=0．088，P=0．244）；IL-27p28的mRNA表达水平在治疗一年后明显升高，为治疗前的2．18倍，差异有统计学意义（P=0．027），治疗两年后又基本恢复至治疗前水平。结论哮喘患儿特异性免疫治疗有效；Foxp3转录因子和IL-27在哮喘的发生和SIT治疗中起重要作用。

Objective Objective To investigate the expression of Foxp5 transcription factor, Interleu- kin-27 （IL-27） p28 and EBI3 in children with allergic asthma treated with specific immunotherapy （SIT）. Methods According to the time of antigen-specific immunotherapy, the periphery venous blood of 39 children with allergic asthma were harvested at the time of one year before SIT, one year and two years after SIT respec- tively, then the peripheral blood mononuclear cells （PBMCs） were separated and total RNA was extracted and reverse transcribed into cDNA. The expression of FoxpS, IL-27p28 and EBIS mRNA in PBMCs were detected by real-time PCR. Meanwhile, the clinical effects of the treatment were observed. Results According to the time of SIT treatment, the clinical symptom was significantly alleviated, Comparing to the expression before SIT treatment, 1 or 2 years after SIT treatment, the expression of Foxp3 mRNA in peripheral blood was significantly increased to 5.03 times or 1.93 times the expression at pretreatment respectively （ P = 0. 0008, P = 0. 033 ）. The expression of IL-27 EBI3 mRNA was increased to 1.56 times and 1.32 times the pretreatment respectively （P =0. 088, P =0. 244）. The expression of IL-27 p28 mRNA significantly increased to 2.18 times the pre- treatment at 1 year after SIT treatment （ P = 0. 027 ）, but its expression returned to basic level as pretreatment at 2 years after of SIT treatment. Conclusions SIT is an effective therapy for the children with allergic asth- ma. Therefore, Foxp3 and IL-27 may play important roles in the pathogontosis of asthma.